bimagrumab and tirzepatide 📌 Why Isn't Anyone Talking About BIMAGRUMAB?! 🤯💪 Because it's not a “peptide” — it's a massive monoclonal antibody 👀 Let's break it down… ✨ What It Is • 🧬 Human monoclonal Antibody blockade of activin type

The structural barriers (no NDC codes, no PBM contracts) would require a different discount mechanism

This distinction also separates a compounded drug from a generic one: While the latter has an abbreviated FDA-approval process (since the existing brand-name drug has already been shown safe and efficacious), the maker still has to prove to the FDA that their version is equivalent to the OG on both fronts

Its best to minimize or avoid it, especially during dose adjustments

We all have a unique genome, metabolism and microbiome

112 ZhangD

When TSC1/TSC2 is phosphorylated by AKT1 it is less effective at stimulating the GTPase activity of Rheb and therefore Rheb activation of mTOR will remain high as is the case in response to insulin action